13th Jul 2006 11:39
Hikma Pharmaceuticals Plc13 July 2006 Section 198 Notification London, 13 July 2006 - On 13 July 2006, Hikma Pharmaceuticals PLC (LSE: HIK)(DIFX: HIK) ("the Company") received notification from The Capital GroupCompanies, Inc., pursuant to Section 198 Companies Act 1985, that at the closeof its business on 11 July 2006, The Capital Group Companies, Inc., on behalfof its affiliates, including Capital Research and Management Company, had aninterest in 7,811,400 ordinary shares of 10p each in the Company, which represents 4.668 per cent of the issued ordinary share capital of the Company,as follows: No. of shares Percent of ordinary shares outstandingThe Capital Group Companies, Inc. 7,811,400 4.668%held as follows:Capital Research and Management Company 7,811,400 4.668%of which:SMALLCAP World Fund 5,069,153 3.029% Registered holders: State Street Nominees Limited 5,069,153Chase Nominees Limited 2,742,247 Total 7,811,400 - ENDS - Enquiries: Hikma Pharmaceuticals PLC +44 20 7399 2670Henry Knowles, Company SecretarySusan Ringdal, Investor Relations DirectorBrunswick Group LLP +44 20 7404 5959Jon Coles / Justine McIlroy / Alex Tweed Notes to Editors About HikmaHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2005, the Grouphad revenue of $262 million and profit attributable to shareholders of $44million. At 31 December 2005, the Group had over 1,800 employees. For news andother information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals